Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abacavir + Protease Inhibitors in Antiretroviral-Naive HIV Patients
NCT00002440Phase 2Completed
- Sponsor
- GSK
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abacavir in human immunodeficiency virus type 1 infection (HIV-1) (5 arms), sponsored by GSK. Primary endpoints: Steady-State Pharmacokinetics of 1592U89 and Protease Inhibitors at 48 weeks, Safety and Tolerability at 48 weeks and 1 more. Status: completed.
02
Drugs
abacavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00002440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002440.